Related Experiment Video

Updated: Jun 10, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results

Ornella Durin1, Claudio Pedrinazzi, Giuseppe Inama

  • 1Division of Cardiology, Cardiocerebrovascular Department, Ospedale Maggiore, largo U. Dossena 2, Crema, Italy.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|August 24, 2010
PubMed

Insights

New research explores non-antiarrhythmic drugs targeting atrial remodeling to prevent atrial fibrillation (AF). Despite promising avenues, recent studies like GISSI AF show limited efficacy, necessitating a re-evaluation of these therapies for AF recurrence.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Research

Background:

  • Atrial fibrillation (AF) is a prevalent arrhythmia with increasing incidence.
  • Current antiarrhythmic drugs show limited long-term efficacy for AF management.
  • Atrial remodeling is a key substrate for AF, prompting research into non-traditional therapies.

Purpose of the Study:

  • To reassess the rationale for using non-antiarrhythmic drugs targeting the renin-angiotensin system for AF.
  • To review clinical literature on these agents since 1999.
  • To discuss the implications of the GISSI AF study on this therapeutic approach.

Main Methods:

  • Literature review of studies investigating renin-angiotensin system modulators for AF.
  • Critical analysis of clinical trial data, including the GISSI AF study.
  • Re-evaluation of the underlying mechanisms and therapeutic potential.

Main Results:

  • Previous research on renin-angiotensin system modulators yielded mixed results, with some promising but others disappointing outcomes.
  • The GISSI AF study found no significant difference between the active drug and placebo in preventing AF recurrences.
  • The efficacy of these non-antiarrhythmic drugs in managing AF requires further critical assessment.

Conclusions:

  • The use of renin-angiotensin system modulators as an 'antiarrhythmic' strategy for AF warrants careful reconsideration.
  • Despite initial promise, clinical evidence suggests limited effectiveness in preventing AF recurrence.
  • Further research is needed to identify effective strategies for preventing and controlling AF onset and recurrence.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...